In this episode, Ayesha and the editorial team spoke with Peter Sallstig, MD, MBA, Global Head of Product Development Division and Chief Medical Officer (CMO) at Santen Pharmaceuticals, a biotech company focused on leveraging key, innovative technologies to develop solutions for eye-related problems worldwide. Recently, Santen received FDA approval for the company’s OMLONTI eye drops for the reduction of elevated intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. In this interview, Dr. Sallstig spoke about OMLONTI, what makes his work and team at Santen so special and the company’s commitment to innovations in eye health. For more life science and medical device content, visit the Xtalks Vitals homepage.Follow Us on Social MediaTwitter: @Xtalks Instagram: @Xtalks Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured